Search Results for: MTOR

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • Co-inhibition by CTLA4
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • KEAP1-NFE2L2 pathway
  • SARS-CoV-2 targets host intracellular signalling and regulatory pathways
  • Mitochondrial unfolded protein response (UPRmt)
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
Novel AKT1S1 AKT1 substrate 1
  • MTOR signalling
  • mTORC1-mediated signalling
  • AKT phosphorylates targets in the cytosol
  • HSF1-dependent transactivation
  • Constitutive Signaling by AKT1 E17K in Cancer
Novel AMBRA1 autophagy and beclin 1 regulator 1
  • Macroautophagy
Novel BCL2L1 BCL2 like 1
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Interleukin-4 and Interleukin-13 signaling
  • The NLRP1 inflammasome
  • RAS processing
  • SARS-CoV-1-mediated effects on programmed cell death
  • STAT5 activation downstream of FLT3 ITD mutants
  • NFE2L2 regulating tumorigenic genes
  • 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID
  • Gossypol
Novel C7orf25 chromosome 7 open reading frame 25
Novel CA6 carbonic anhydrase 6
  • Reversible hydration of carbon dioxide
  • Benzthiazide
  • Cyclothiazide
  • Zonisamide
  • Mafenide
  • Ellagic acid
Novel CDC37 cell division cycle 37, HSP90 cochaperone
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Downregulation of ERBB2 signaling
  • RHOBTB2 GTPase cycle
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
Novel CFP complement factor properdin
  • Alternative complement activation
  • Activation of C3 and C5
  • Defective B3GALTL causes PpS
  • O-glycosylation of TSR domain-containing proteins
  • Neutrophil degranulation
  • Regulation of Complement cascade
  • Alternative complement pathway component defects, including the following four diseases: Factor B deficiency; Factor D deficiency; Factor H deficiency; Properdin deficiency
Novel CLIP1 CAP-Gly domain containing linker protein 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases activate IQGAPs
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
  • Signaling by LTK in cancer
Novel DCP2 decapping mRNA 2
  • ATF4 activates genes in response to endoplasmic reticulum stress
  • mRNA decay by 5' to 3' exoribonuclease
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
Novel EIF3F eukaryotic translation initiation factor 3 subunit F
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Translation initiation complex formation
  • Formation of a pool of free 40S subunits
  • Formation of the ternary complex, and subsequently, the 43S complex
  • Ribosomal scanning and start codon recognition
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Quercetin
Novel EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1
  • mTORC1-mediated signalling
  • Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
Novel EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2
Novel EP300 EP300 lysine acetyltransferase
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Polo-like kinase mediated events
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • NOTCH2 intracellular domain regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • HATs acetylate histones
  • Attenuation phase
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • B-WICH complex positively regulates rRNA expression
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • CD209 (DC-SIGN) signaling
  • Metalloprotease DUBs
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • Activation of the TFAP2 (AP-2) family of transcription factors
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • Regulation of RUNX3 expression and activity
  • RUNX3 regulates p14-ARF
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • FOXO-mediated transcription of cell death genes
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • STAT3 nuclear events downstream of ALK signaling
  • Heme signaling
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • Nuclear events mediated by NFE2L2
  • Formation of paraxial mesoderm
  • NFE2L2 regulating inflammation associated genes
  • NFE2L2 regulating anti-oxidant/detoxification enzymes
  • NFE2L2 regulates pentose phosphate pathway genes
  • NFE2L2 regulating tumorigenic genes
  • NFE2L2 regulating MDR associated enzymes
  • NFE2L2 regulating ER-stress associated genes
  • Regulation of NFE2L2 gene expression
  • Regulation of NFE2L2 gene expression
  • Zygotic genome activation (ZGA)
  • Evasion by RSV of host interferon responses
  • TGFBR3 expression
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
  • Rubinstein-Taybi syndrome
Novel ESR1 estrogen receptor 1
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Ovarian tumor domain proteases
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • RUNX1 regulates estrogen receptor mediated transcription
  • ESR-mediated signaling
  • RUNX1 regulates transcription of genes involved in WNT signaling
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent gene expression
  • Mitochondrial unfolded protein response (UPRmt)
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Alveolar Cells
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated estrogens
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Lindane
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone acetate
  • Testosterone
  • Mitotane
  • Estrone
  • Tamoxifen
  • Hexachlorophene
  • Estradiol
  • Ethynodiol diacetate
  • Dobutamine
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinylestradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Oxybenzone
  • Allylestrenol
  • Zinc
  • Genistein
  • Prasterone
  • Benzophenone
  • Equilin
  • Compound 19
  • Resveratrol
  • Compound 18
  • Phthalic Acid
  • Pyrazole
  • Stanolone
  • Naringenin
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Quercetin
  • Afimoxifene
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estrone sulfate
  • Quinestrol
  • Phenolphthalein
  • Permethrin
  • Ospemifene
  • AP1081
  • Custirsen
  • NP-50301
  • CHF 4227
  • TAS-108
  • Lasofoxifene
  • Arzoxifene
  • Elacestrant
  • Bazedoxifene
  • Methyltestosterone
  • beta-Naphthoflavone
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • din-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • Hexestrol
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • Erteberel
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
  • Tibolone
  • Eugenol
  • Synthetic Conjugated Estrogens, A
  • Synthetic Conjugated Estrogens, B
  • Polyestradiol phosphate
  • Norethynodrel
  • Octocrylene
  • Homosalate
  • Enzacamene
  • Zeranol
  • Ractopamine
  • Gestrinone
  • Estetrol
  • Propyl Gallate
  • Ormeloxifene
  • 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
  • Testosterone cypionate
  • Testosterone enanthate
  • Stanolone acetate
  • Estradiol acetate
  • Estradiol benzoate
  • Estradiol cypionate
  • Estradiol dienanthate
  • Estradiol valerate
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Estriol tripropionate
  • Fluoroestradiol F-18
Novel FBXO8 F-box protein 8
Novel FKBP1A FKBP prolyl isomerase 1A
  • mTORC1-mediated signalling
  • Calcineurin activates NFAT
  • Calcineurin activates NFAT
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGFBR1 LBD Mutants in Cancer
  • Potential therapeutics for SARS
  • SARS-CoV-1 activates/modulates innate immune responses
  • Pimecrolimus
  • Tacrolimus
  • (3R)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-L-phenylalanine ethyl ester
  • {3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid
  • Gpi-1046
  • Methyl Methylsulfinylmethyl Sulfide
  • FKB-001
  • Heptyl glucoside
  • L-709,587
  • (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine
  • 4-hydroxybutan-2-one
  • GPI-1485
  • Myristic acid
  • (21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE
  • Dorsomorphin
Novel FKBP8 FKBP prolyl isomerase 8
  • Ub-specific processing proteases
Novel FLNA filamin A
  • Platelet degranulation
  • GP1b-IX-V activation signalling
  • Cell-extracellular matrix interactions
  • RHO GTPases activate PAKs
  • OAS antiviral response
  • Artenimol
  • FG syndrome (FGS); Opitz-Kaveggia syndrome
  • Periventricular nodular heterotopia (PVNH)
  • Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
  • Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia
Novel GPHN gephyrin
  • Molybdenum cofactor biosynthesis
  • Formic acid
  • Imidazole
  • Propanoic acid
  • Hyperekplexia

Page 1 out of 7 pages